Cordlife launches newborn metabolic screening service in Hong Kong

SINGAPORE (May 2): HealthBaby Biotech (Hong Kong), a wholly-owned subsidiary of Cordlife Group, has launched a newborn metabolic screening service in Hong Kong.

This comes as part of Cordlife’s move to expand its diagnostics business, says the group in a press release issued on Wednesday.

Named Metascreen, the service uses urine instead of blood to detect over 100 inherited metabolic disorders – which is much more than what can be detected by conventional newborn metabolic screening tests currently available in Hong Kong, according to the group.

---

Related Stories

• Unveiling value opportunities in energy, healthcare and technology
• ASML hit with new limits on chip gear exports to China
• Citing more sustainable lease agreement, DBS initiates coverage of First REIT with 'buy' call and 30 cents target price

---